Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
39
IART Quote, Financials, Valuation and Earnings
Last price:
$12.21
Seasonality move
:
-3.87%
Day range:
$11.87 - $12.20
52-week range:
$10.60 - $25.45
Dividend yield:
0%
P/E ratio:
70.14x
P/S ratio:
0.56x
P/B ratio:
0.90x
Volume:
694.7K
Avg. volume:
709.7K
1-year change:
-52.69%
Market cap:
$938.6M
Revenue:
$1.6B
EPS (TTM):
-$6.46
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
IART
Integra LifeSciences Holdings Corp.
|
$429.6M | $0.80 | 2.48% | 217.65% | $15.50 |
|
BAX
Baxter International, Inc.
|
$2.8B | $0.54 | -0.44% | 26.94% | $21.63 |
|
BDX
Becton, Dickinson & Co.
|
$5.1B | $2.80 | -10.99% | 159.47% | $195.38 |
|
IRTC
iRhythm Holdings, Inc.
|
$202.6M | $0.06 | 21.12% | -48.99% | $221.27 |
|
SYK
Stryker Corp.
|
$7.1B | $4.40 | 8.36% | 77.06% | $424.40 |
|
TNDM
Tandem Diabetes Care, Inc.
|
$277.2M | -$0.09 | 6.5% | -78.26% | $25.91 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
IART
Integra LifeSciences Holdings Corp.
|
$12.05 | $15.50 | $938.6M | 70.14x | $0.00 | 0% | 0.56x |
|
BAX
Baxter International, Inc.
|
$21.34 | $21.63 | $11B | 167.20x | $0.01 | 2.44% | 0.98x |
|
BDX
Becton, Dickinson & Co.
|
$182.47 | $195.38 | $51.9B | 29.80x | $0.83 | 1.8% | 2.39x |
|
IRTC
iRhythm Holdings, Inc.
|
$158.88 | $221.27 | $5.1B | -- | $0.00 | 0% | 7.19x |
|
SYK
Stryker Corp.
|
$372.66 | $424.40 | $142.6B | 44.37x | $0.88 | 0.91% | 5.73x |
|
TNDM
Tandem Diabetes Care, Inc.
|
$18.52 | $25.91 | $1.3B | -- | $0.00 | 0% | 1.23x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
IART
Integra LifeSciences Holdings Corp.
|
65.91% | -0.228 | 179.84% | 1.47x |
|
BAX
Baxter International, Inc.
|
61.48% | -0.563 | 99.84% | 1.33x |
|
BDX
Becton, Dickinson & Co.
|
43.59% | -0.585 | 44.99% | 0.40x |
|
IRTC
iRhythm Holdings, Inc.
|
85.74% | 2.239 | 13.23% | 4.47x |
|
SYK
Stryker Corp.
|
42.19% | 0.338 | 12.42% | 1.07x |
|
TNDM
Tandem Diabetes Care, Inc.
|
77.16% | 1.906 | 54.61% | 1.79x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
IART
Integra LifeSciences Holdings Corp.
|
$226.1M | $25.9M | -14.85% | -37.15% | 6.43% | $25.8M |
|
BAX
Baxter International, Inc.
|
$870M | $117M | -5.13% | -12.97% | 3.93% | $444M |
|
BDX
Becton, Dickinson & Co.
|
$2.4B | $700M | 3.93% | 6.94% | 13.33% | $549M |
|
IRTC
iRhythm Holdings, Inc.
|
$137.1M | -$4M | -6.2% | -54.18% | -2.08% | $20.1M |
|
SYK
Stryker Corp.
|
$4.5B | $2B | 8.59% | 15.17% | 27.74% | $1.9B |
|
TNDM
Tandem Diabetes Care, Inc.
|
$134.3M | -$20.1M | -31.16% | -110.24% | -8.05% | $4.2M |
Integra LifeSciences Holdings Corp. vs. Competitors
-
Which has Higher Returns IART or BAX?
Baxter International, Inc. has a net margin of -1.34% compared to Integra LifeSciences Holdings Corp.'s net margin of -34.8%. Integra LifeSciences Holdings Corp.'s return on equity of -37.15% beat Baxter International, Inc.'s return on equity of -12.97%.
Company Gross Margin Earnings Per Share Invested Capital IARTIntegra LifeSciences Holdings Corp.56.24% -$0.07 $3B BAXBaxter International, Inc.29.25% -$2.16 $15.9B -
What do Analysts Say About IART or BAX?
Integra LifeSciences Holdings Corp. has a consensus price target of $15.50, signalling upside risk potential of 28.63%. On the other hand Baxter International, Inc. has an analysts' consensus of $21.63 which suggests that it could grow by 1.38%. Given that Integra LifeSciences Holdings Corp. has higher upside potential than Baxter International, Inc., analysts believe Integra LifeSciences Holdings Corp. is more attractive than Baxter International, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IARTIntegra LifeSciences Holdings Corp.2 4 2 BAXBaxter International, Inc.2 13 1 -
Is IART or BAX More Risky?
Integra LifeSciences Holdings Corp. has a beta of 1.036, which suggesting that the stock is 3.641% more volatile than S&P 500. In comparison Baxter International, Inc. has a beta of 0.593, suggesting its less volatile than the S&P 500 by 40.747%.
-
Which is a Better Dividend Stock IART or BAX?
Integra LifeSciences Holdings Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Baxter International, Inc. offers a yield of 2.44% to investors and pays a quarterly dividend of $0.01 per share. Integra LifeSciences Holdings Corp. pays -- of its earnings as a dividend. Baxter International, Inc. pays out 180.98% of its earnings as a dividend.
-
Which has Better Financial Ratios IART or BAX?
Integra LifeSciences Holdings Corp. quarterly revenues are $402.1M, which are smaller than Baxter International, Inc. quarterly revenues of $3B. Integra LifeSciences Holdings Corp.'s net income of -$5.4M is higher than Baxter International, Inc.'s net income of -$1B. Notably, Integra LifeSciences Holdings Corp.'s price-to-earnings ratio is 70.14x while Baxter International, Inc.'s PE ratio is 167.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integra LifeSciences Holdings Corp. is 0.56x versus 0.98x for Baxter International, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IARTIntegra LifeSciences Holdings Corp.0.56x 70.14x $402.1M -$5.4M BAXBaxter International, Inc.0.98x 167.20x $3B -$1B
-
Which has Higher Returns IART or BDX?
Becton, Dickinson & Co. has a net margin of -1.34% compared to Integra LifeSciences Holdings Corp.'s net margin of 7.27%. Integra LifeSciences Holdings Corp.'s return on equity of -37.15% beat Becton, Dickinson & Co.'s return on equity of 6.94%.
Company Gross Margin Earnings Per Share Invested Capital IARTIntegra LifeSciences Holdings Corp.56.24% -$0.07 $3B BDXBecton, Dickinson & Co.45.91% $1.34 $44.8B -
What do Analysts Say About IART or BDX?
Integra LifeSciences Holdings Corp. has a consensus price target of $15.50, signalling upside risk potential of 28.63%. On the other hand Becton, Dickinson & Co. has an analysts' consensus of $195.38 which suggests that it could grow by 7.08%. Given that Integra LifeSciences Holdings Corp. has higher upside potential than Becton, Dickinson & Co., analysts believe Integra LifeSciences Holdings Corp. is more attractive than Becton, Dickinson & Co..
Company Buy Ratings Hold Ratings Sell Ratings IARTIntegra LifeSciences Holdings Corp.2 4 2 BDXBecton, Dickinson & Co.4 9 0 -
Is IART or BDX More Risky?
Integra LifeSciences Holdings Corp. has a beta of 1.036, which suggesting that the stock is 3.641% more volatile than S&P 500. In comparison Becton, Dickinson & Co. has a beta of 0.248, suggesting its less volatile than the S&P 500 by 75.233%.
-
Which is a Better Dividend Stock IART or BDX?
Integra LifeSciences Holdings Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Becton, Dickinson & Co. offers a yield of 1.8% to investors and pays a quarterly dividend of $0.83 per share. Integra LifeSciences Holdings Corp. pays -- of its earnings as a dividend. Becton, Dickinson & Co. pays out 71.53% of its earnings as a dividend. Becton, Dickinson & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios IART or BDX?
Integra LifeSciences Holdings Corp. quarterly revenues are $402.1M, which are smaller than Becton, Dickinson & Co. quarterly revenues of $5.3B. Integra LifeSciences Holdings Corp.'s net income of -$5.4M is lower than Becton, Dickinson & Co.'s net income of $382M. Notably, Integra LifeSciences Holdings Corp.'s price-to-earnings ratio is 70.14x while Becton, Dickinson & Co.'s PE ratio is 29.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integra LifeSciences Holdings Corp. is 0.56x versus 2.39x for Becton, Dickinson & Co.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IARTIntegra LifeSciences Holdings Corp.0.56x 70.14x $402.1M -$5.4M BDXBecton, Dickinson & Co.2.39x 29.80x $5.3B $382M
-
Which has Higher Returns IART or IRTC?
iRhythm Holdings, Inc. has a net margin of -1.34% compared to Integra LifeSciences Holdings Corp.'s net margin of -2.7%. Integra LifeSciences Holdings Corp.'s return on equity of -37.15% beat iRhythm Holdings, Inc.'s return on equity of -54.18%.
Company Gross Margin Earnings Per Share Invested Capital IARTIntegra LifeSciences Holdings Corp.56.24% -$0.07 $3B IRTCiRhythm Holdings, Inc.71.09% -$0.16 $854.9M -
What do Analysts Say About IART or IRTC?
Integra LifeSciences Holdings Corp. has a consensus price target of $15.50, signalling upside risk potential of 28.63%. On the other hand iRhythm Holdings, Inc. has an analysts' consensus of $221.27 which suggests that it could grow by 39.27%. Given that iRhythm Holdings, Inc. has higher upside potential than Integra LifeSciences Holdings Corp., analysts believe iRhythm Holdings, Inc. is more attractive than Integra LifeSciences Holdings Corp..
Company Buy Ratings Hold Ratings Sell Ratings IARTIntegra LifeSciences Holdings Corp.2 4 2 IRTCiRhythm Holdings, Inc.12 1 0 -
Is IART or IRTC More Risky?
Integra LifeSciences Holdings Corp. has a beta of 1.036, which suggesting that the stock is 3.641% more volatile than S&P 500. In comparison iRhythm Holdings, Inc. has a beta of 1.062, suggesting its more volatile than the S&P 500 by 6.245%.
-
Which is a Better Dividend Stock IART or IRTC?
Integra LifeSciences Holdings Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iRhythm Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Integra LifeSciences Holdings Corp. pays -- of its earnings as a dividend. iRhythm Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IART or IRTC?
Integra LifeSciences Holdings Corp. quarterly revenues are $402.1M, which are larger than iRhythm Holdings, Inc. quarterly revenues of $192.9M. Integra LifeSciences Holdings Corp.'s net income of -$5.4M is lower than iRhythm Holdings, Inc.'s net income of -$5.2M. Notably, Integra LifeSciences Holdings Corp.'s price-to-earnings ratio is 70.14x while iRhythm Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integra LifeSciences Holdings Corp. is 0.56x versus 7.19x for iRhythm Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IARTIntegra LifeSciences Holdings Corp.0.56x 70.14x $402.1M -$5.4M IRTCiRhythm Holdings, Inc.7.19x -- $192.9M -$5.2M
-
Which has Higher Returns IART or SYK?
Stryker Corp. has a net margin of -1.34% compared to Integra LifeSciences Holdings Corp.'s net margin of 11.84%. Integra LifeSciences Holdings Corp.'s return on equity of -37.15% beat Stryker Corp.'s return on equity of 15.17%.
Company Gross Margin Earnings Per Share Invested Capital IARTIntegra LifeSciences Holdings Corp.56.24% -$0.07 $3B SYKStryker Corp.62.81% $2.20 $38.8B -
What do Analysts Say About IART or SYK?
Integra LifeSciences Holdings Corp. has a consensus price target of $15.50, signalling upside risk potential of 28.63%. On the other hand Stryker Corp. has an analysts' consensus of $424.40 which suggests that it could grow by 13.88%. Given that Integra LifeSciences Holdings Corp. has higher upside potential than Stryker Corp., analysts believe Integra LifeSciences Holdings Corp. is more attractive than Stryker Corp..
Company Buy Ratings Hold Ratings Sell Ratings IARTIntegra LifeSciences Holdings Corp.2 4 2 SYKStryker Corp.12 8 0 -
Is IART or SYK More Risky?
Integra LifeSciences Holdings Corp. has a beta of 1.036, which suggesting that the stock is 3.641% more volatile than S&P 500. In comparison Stryker Corp. has a beta of 0.873, suggesting its less volatile than the S&P 500 by 12.679%.
-
Which is a Better Dividend Stock IART or SYK?
Integra LifeSciences Holdings Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stryker Corp. offers a yield of 0.91% to investors and pays a quarterly dividend of $0.88 per share. Integra LifeSciences Holdings Corp. pays -- of its earnings as a dividend. Stryker Corp. pays out 40.48% of its earnings as a dividend. Stryker Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios IART or SYK?
Integra LifeSciences Holdings Corp. quarterly revenues are $402.1M, which are smaller than Stryker Corp. quarterly revenues of $7.2B. Integra LifeSciences Holdings Corp.'s net income of -$5.4M is lower than Stryker Corp.'s net income of $849M. Notably, Integra LifeSciences Holdings Corp.'s price-to-earnings ratio is 70.14x while Stryker Corp.'s PE ratio is 44.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integra LifeSciences Holdings Corp. is 0.56x versus 5.73x for Stryker Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IARTIntegra LifeSciences Holdings Corp.0.56x 70.14x $402.1M -$5.4M SYKStryker Corp.5.73x 44.37x $7.2B $849M
-
Which has Higher Returns IART or TNDM?
Tandem Diabetes Care, Inc. has a net margin of -1.34% compared to Integra LifeSciences Holdings Corp.'s net margin of -8.49%. Integra LifeSciences Holdings Corp.'s return on equity of -37.15% beat Tandem Diabetes Care, Inc.'s return on equity of -110.24%.
Company Gross Margin Earnings Per Share Invested Capital IARTIntegra LifeSciences Holdings Corp.56.24% -$0.07 $3B TNDMTandem Diabetes Care, Inc.53.88% -$0.31 $582.2M -
What do Analysts Say About IART or TNDM?
Integra LifeSciences Holdings Corp. has a consensus price target of $15.50, signalling upside risk potential of 28.63%. On the other hand Tandem Diabetes Care, Inc. has an analysts' consensus of $25.91 which suggests that it could grow by 41.16%. Given that Tandem Diabetes Care, Inc. has higher upside potential than Integra LifeSciences Holdings Corp., analysts believe Tandem Diabetes Care, Inc. is more attractive than Integra LifeSciences Holdings Corp..
Company Buy Ratings Hold Ratings Sell Ratings IARTIntegra LifeSciences Holdings Corp.2 4 2 TNDMTandem Diabetes Care, Inc.7 14 0 -
Is IART or TNDM More Risky?
Integra LifeSciences Holdings Corp. has a beta of 1.036, which suggesting that the stock is 3.641% more volatile than S&P 500. In comparison Tandem Diabetes Care, Inc. has a beta of 1.683, suggesting its more volatile than the S&P 500 by 68.285%.
-
Which is a Better Dividend Stock IART or TNDM?
Integra LifeSciences Holdings Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tandem Diabetes Care, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Integra LifeSciences Holdings Corp. pays -- of its earnings as a dividend. Tandem Diabetes Care, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IART or TNDM?
Integra LifeSciences Holdings Corp. quarterly revenues are $402.1M, which are larger than Tandem Diabetes Care, Inc. quarterly revenues of $249.3M. Integra LifeSciences Holdings Corp.'s net income of -$5.4M is higher than Tandem Diabetes Care, Inc.'s net income of -$21.2M. Notably, Integra LifeSciences Holdings Corp.'s price-to-earnings ratio is 70.14x while Tandem Diabetes Care, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integra LifeSciences Holdings Corp. is 0.56x versus 1.23x for Tandem Diabetes Care, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IARTIntegra LifeSciences Holdings Corp.0.56x 70.14x $402.1M -$5.4M TNDMTandem Diabetes Care, Inc.1.23x -- $249.3M -$21.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
23
CAR alert for Feb 20
Avis Budget Group, Inc. [CAR] is down 0.3% over the past day.
Buy
75
HYMC alert for Feb 20
Hycroft Mining Holding Corp. [HYMC] is down 2.47% over the past day.
Sell
1
EPAM alert for Feb 20
EPAM Systems, Inc. [EPAM] is down 0.11% over the past day.
